Results 241 to 250 of about 1,329,149 (334)

Adverse immunostimulation in early phase clinical trials: Key findings and recommendations based on the investigator's clinical experience

British Journal of Clinical Pharmacology, EarlyView.
Problem setting The emergence of therapeutic proteins has coincided with an increase of acute adverse immunostimulation (AIS). AIS has occured in clinical trials despite compliance with regulatory guidelines on preclinical evaluation and its incidence is anticipated to increase even further.
Juliette A. van den Noort, Marella C. E. van Ruissen, Lisanne C. A. Smidt, Naomi B. Klarenbeek, Philip H. K. Kremer, Manon A. A. Jansen, Jacobus Burggraaf, Joop M. A. van Gerven, Matthijs Moerland   +8 more
wiley   +1 more source

Interferon gamma rebalances immunopathological signatures in chronic granulomatous disease through metabolic rewiring. [PDF]

Blood Adv
Bruno M, Kröger C, Ferreira AV, Zhang B, Röring RJ, Liu R, van der Made CI, van Rhijn N, Groh L, Klück V, Janssen NAF, Li W, Rosati D, Alaswad A, Tercan H, Saiz J, Gonzalez-Riano C, van Uelft M, Gaal OI, Müller S, Ferreira HJ, Warnat-Herresthal S, Becker M, Holsten L, Kraut M, Schulte-Schrepping J, Bonaguro L, Händler K, Cunha C, Schmolz M, Schultze JL, Joosten LAB, Barbas C, Netea MG, Li Y, Aschenbrenner AC, Carvalho A, van de Veerdonk FL.   +37 more
europepmc   +1 more source

Age‐related differences in hydroxychloroquine‐associated adverse events: A pharmacovigilance study based on the FDA Adverse Event Reporting System

British Journal of Clinical Pharmacology, EarlyView.
Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun, Jingrong Yang, Lei Wan, Xia Xu, Jing Wang   +4 more
wiley   +1 more source

Alternative Splicing as a Modulator of the Interferon-Gamma Pathway. [PDF]

Cancers (Basel)
Suri P, Badalov A, Ruggiu M.
europepmc   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source

Variable clinical features and delayed diagnosis in six Chinese patients with anti-interferon-gamma autoantibodies: a retrospective analysis in a university hospital in China. [PDF]

BMC Immunol
Zhang J, Ni J, Kong W, Liu J, Chen Y.
europepmc   +1 more source

Cold atmospheric plasma‐mediated tumor microenvironment remodeling for cancer treatment

BMEMat, EarlyView.
Schematic presentation of CAP‐mediated TME remodeling. This review summarizes recent efforts in cold atmospheric plasma (CAP) application in cancer treatment, highlighting the anticancer potential of CAP, molecular mechanisms, and future perspectives for further improvement and clinical translation.
Israr Khan, Qiujie Fang, Cao Fei, Ziyuan Wang, Zhaowei Chen, Guojun Chen, Zhiming Xu, Shu Xu, Zhitong Chen   +8 more
wiley   +1 more source

Pathomics-based machine learning model predicts interferon-gamma expression in head and neck squamous cell carcinoma patients. [PDF]

Front Immunol
Yu J, Teng W, Yu G, Wang Z, Bai B, Wang Y, Wang F.   +6 more
europepmc   +1 more source

Nanomaterials‐mediated glycolysis rewriting to potentiate tumor immunotherapy

BMEMat, EarlyView.
This review systematically summarizes cutting‐edge advances in glycolysis‐rewiring nanomedicines, emphasizing their mechanisms in reversing immunosuppression and reinvigorating antitumor immune responses. Challenges in clinical translation and future directions for designing multifunctional metabolic‐immune modulators are also critically discussed ...
Zilin Ma, Songyan Li, Jie Yan, Xuechun Wang, Wen Zhao, Yunxuan Song, Dongdong Liu, Jianwei Jiao, Xiuying Duan, Guiqiang Zhang   +9 more
wiley   +1 more source

Interferon-gamma-inducible protein 30 prevents IFN-γ-receptor 1 degradation to maintain PD-L1 and MHC-II levels in metastatic melanoma. [PDF]

Cell Commun Signal
Mizuno S, Mizuno Y, Abe K, Macy AM, Chong KK, Kobayashi Y, Hastings KT, Hoon DSB, Bustos MA.   +8 more
europepmc   +1 more source